OUTLOOK THERAPEUTICS INC (OTLK) Fundamental Analysis & Valuation

NASDAQ:OTLK • US69012T3059

Current stock price

0.249 USD
+0.03 (+12.06%)
At close:
0.2453 USD
0 (-1.49%)
After Hours:

This OTLK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OTLK Profitability Analysis

1.1 Basic Checks

  • In the past year OTLK has reported negative net income.
  • OTLK had a negative operating cash flow in the past year.
  • In the past 5 years OTLK always reported negative net income.
  • OTLK had a negative operating cash flow in each of the past 5 years.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -563.97%, OTLK is not doing good in the industry: 94.58% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -563.97%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K -1.5K

1.3 Margins

  • With a decent Gross Margin value of 19.23%, OTLK is doing good in the industry, outperforming 71.57% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for OTLK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. OTLK Health Analysis

2.1 Basic Checks

  • OTLK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for OTLK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -60.82, we must say that OTLK is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -60.82, OTLK is doing worse than 92.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.82
ROIC/WACCN/A
WACC8.62%
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

2.3 Liquidity

  • A Current Ratio of 0.35 indicates that OTLK may have some problems paying its short term obligations.
  • OTLK has a Current ratio of 0.35. This is amonst the worse of the industry: OTLK underperforms 93.04% of its industry peers.
  • OTLK has a Quick Ratio of 0.35. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.28, OTLK is doing worse than 93.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.28
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. OTLK Growth Analysis

3.1 Past

  • The earnings per share for OTLK have decreased strongly by -51.11% in the last year.
EPS 1Y (TTM)-51.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 10.99% on average over the next years. This is quite good.
  • OTLK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.18% yearly.
EPS Next Y-49.76%
EPS Next 2Y-4.93%
EPS Next 3Y17.82%
EPS Next 5Y10.99%
Revenue Next Year215.74%
Revenue Next 2Y193.72%
Revenue Next 3Y50.35%
Revenue Next 5Y35.18%

3.3 Evolution

OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 2033 10M 20M 30M 40M 50M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

0

4. OTLK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OTLK. In the last year negative earnings were reported.
  • Also next year OTLK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • OTLK's earnings are expected to grow with 17.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.93%
EPS Next 3Y17.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OTLK Dividend Analysis

5.1 Amount

  • OTLK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OTLK Fundamentals: All Metrics, Ratios and Statistics

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (4/10/2026, 8:00:02 PM)

After market: 0.2453 0 (-1.49%)

0.249

+0.03 (+12.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-13
Inst Owners6.86%
Inst Owner Change0%
Ins Owners0.03%
Ins Owner Change0%
Market Cap26.05M
Revenue(TTM)297.50K
Net Income(TTM)-102.86M
Analysts80
Price Target4.25 (1606.83%)
Short Float %4.58%
Short Ratio1.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.32%
Min EPS beat(2)-19.83%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)0.99%
Min EPS beat(4)-37.09%
Max EPS beat(4)34.42%
EPS beat(8)5
Avg EPS beat(8)40.51%
EPS beat(12)8
Avg EPS beat(12)30.37%
EPS beat(16)9
Avg EPS beat(16)17.3%
Revenue beat(2)0
Avg Revenue beat(2)-112.55%
Min Revenue beat(2)-123.57%
Max Revenue beat(2)-101.54%
Revenue beat(4)0
Avg Revenue beat(4)-84.09%
Min Revenue beat(4)-123.57%
Max Revenue beat(4)-11.26%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.91%
PT rev (3m)-59.21%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)36.43%
Revenue NQ rev (1m)-11.41%
Revenue NQ rev (3m)49.15%
Revenue NY rev (1m)-16.19%
Revenue NY rev (3m)-28.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 69.53
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS-0.46
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -563.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.23%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.28
Altman-Z -60.82
F-Score5
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.56%
EPS Next Y-49.76%
EPS Next 2Y-4.93%
EPS Next 3Y17.82%
EPS Next 5Y10.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year215.74%
Revenue Next 2Y193.72%
Revenue Next 3Y50.35%
Revenue Next 5Y35.18%
EBIT growth 1Y29.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.46%
OCF growth 3YN/A
OCF growth 5YN/A

OUTLOOK THERAPEUTICS INC / OTLK Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OUTLOOK THERAPEUTICS INC (OTLK) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OTLK.


Can you provide the valuation status for OUTLOOK THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OUTLOOK THERAPEUTICS INC (OTLK). This can be considered as Overvalued.


Can you provide the profitability details for OUTLOOK THERAPEUTICS INC?

OUTLOOK THERAPEUTICS INC (OTLK) has a profitability rating of 1 / 10.


How financially healthy is OUTLOOK THERAPEUTICS INC?

The financial health rating of OUTLOOK THERAPEUTICS INC (OTLK) is 0 / 10.


Can you provide the expected EPS growth for OTLK stock?

The Earnings per Share (EPS) of OUTLOOK THERAPEUTICS INC (OTLK) is expected to decline by -49.76% in the next year.